The Experts below are selected from a list of 3507 Experts worldwide ranked by ideXlab platform
Marc A. Benninga - One of the best experts on this subject based on the ideXlab platform.
-
Fermented milk containing bifidobacterium lactis dn 173 010 in childhood constipation a randomized double blind controlled trial
Pediatrics, 2011Co-Authors: Merit M Tabbers, Agata Chmielewska, Maaike G Roseboom, Catherine Perrin, Hania Szajewska, Nolwenn Crastes, Johannes B Reitsma, Obbe F Norbruis, Marc A. BenningaAbstract:BACKGROUND: Constipation is a frustrating symptom affecting 3% of children worldwide. A Fermented Dairy Product containing Bifidobacterium lactis strain DN-173 010 was effective in increasing stool frequency in constipated women. Our aim was to assess the effects of this Product in constipated children. METHODS: In this prospective randomized, double-blind, controlled trial, 159 constipated children (defecation frequency RESULTS: Eleven children did not return to any follow-up visit (5 in the probiotic group, 6 in the control group) and were therefore excluded from the final analysis. Thus, 74 children in each group were analyzed. The change in stool frequency from baseline to after 3 weeks of Product consumption increased in both groups, but the difference was not statistically significant (2.9 ± 3.2 in probiotic group versus 2.6 ± 2.6 in control group, P = .35). There were no serious adverse events. CONCLUSIONS: In constipated children, the Fermented Dairy Product containing B lactis strain DN-173 010 did increase stool frequency, but this increase was comparable in the control group. There is currently not sufficient evidence to recommend Fermented Dairy Products containing B lactis strain DN-173 010 in this category of patients. Future studies should focus on whether a longer period of probiotic Products is more effective in children who have a short history of constipation.
-
effect of the consumption of a Fermented Dairy Product containing bifidobacterium lactis dn 173 010 on constipation in childhood a multicentre randomised controlled trial ntrtc 1571
BMC Pediatrics, 2009Co-Authors: Merit M Tabbers, Agata Chmielewska, Maaike G Roseboom, Claire Boudet, Catherine Perrin, Hania Szajewska, Marc A. BenningaAbstract:Background Constipation is a frustrating symptom affecting 3% of children worldwide. Randomised controlled trials show that both polyethylene glycol and lactulose are effective in increasing defecation frequency in children with constipation. However, in 30–50%, these children reported abdominal pain, bloating, flatulence, diarrhoea, nausea and bad taste of the medication. Two recent studies have shown that the Fermented Dairy Product containing Bifidobacterium lactis strain DN-173 010 is effective in increasing stool frequency in constipation-predominant irritable bowel syndrome patients with a defecation frequency < 3/week and in constipated women with a defecation frequency < 3/week. Goal of this study is to determine whether this Fermented Dairy Product is effective in the treatment of constipated children with a defecation frequency < 3/week.
-
effect of the consumption of a Fermented Dairy Product containing bifidobacterium lactis dn 173 010 on constipation in childhood a multicentre randomised controlled trial ntrtc 1571
BMC Pediatrics, 2009Co-Authors: Merit M Tabbers, Agata Chmielewska, Maaike G Roseboom, Claire Boudet, Catherine Perrin, Hania Szajewska, Marc A. BenningaAbstract:Constipation is a frustrating symptom affecting 3% of children worldwide. Randomised controlled trials show that both polyethylene glycol and lactulose are effective in increasing defecation frequency in children with constipation. However, in 30–50%, these children reported abdominal pain, bloating, flatulence, diarrhoea, nausea and bad taste of the medication. Two recent studies have shown that the Fermented Dairy Product containing Bifidobacterium lactis strain DN-173 010 is effective in increasing stool frequency in constipation-predominant irritable bowel syndrome patients with a defecation frequency < 3/week and in constipated women with a defecation frequency < 3/week. Goal of this study is to determine whether this Fermented Dairy Product is effective in the treatment of constipated children with a defecation frequency < 3/week. It is a two nation (The Netherlands and Poland) double-blind, placebo-controlled randomised multicentre trial in which 160 constipated children (age 3–16 years) with a defecation frequency <3/week will be randomly allocated to consume a Fermented Dairy Product containing Bifidobacterium lactis DN-173 010 or a control Product, twice a day, for 3 weeks. During the study all children are instructed to try to defecate on the toilet for 5–10 minutes after each meal (3 times a day) and daily complete a standardized bowel diary. Primary endpoint is stool frequency. Secondary endpoints are stool consistency, faecal incontinence frequency, pain during defecation, digestive symptoms (abdominal pain, flatulence), adverse effects (nausea, diarrhoea, bad taste) and intake of rescue medication (Bisacodyl). Rate of success and rate of responders are also evaluated, with success defined as ≥ 3 bowel movements per week and ≤1 faecal incontinence episode over the last 2 weeks of Product consumption and responder defined as a subject reporting a stool frequency ≥ 3 on the last week of Product consumption. To demonstrate that the success percentage in the intervention group will be 35% and the success percentage in the control group (acidified milk without ferments, toilet training, bowel diary) will be 15%, with alpha 0.05 and power 80%, a total sample size of 160 patients was calculated. This study is aimed to show that the Fermented Dairy Product containing Bifidobacterium lactis strain DN-173 010 is effective in increasing stool frequency after 3 weeks of Product consumption in children with functional constipation and a defecation frequency < 3/week.
Jurgen Schrezenmeir - One of the best experts on this subject based on the ideXlab platform.
-
effects of consumption of a Fermented Dairy Product containing the probiotic lactobacillus casei dn 114 001 on common respiratory and gastrointestinal infections in shift workers in a randomized controlled trial
Journal of The American College of Nutrition, 2010Co-Authors: E Guillemard, Tanguy Jerome, Annlaure Flavigny, Stephan De La Motte, Jurgen SchrezenmeirAbstract:Objective: The risk of infection may be increased in people under stress such as shift workers. This study examined the effect of a Fermented Dairy Product containing the probiotic Lactobacillus casei DN-114 001 (verum) on the incidence of respiratory and gastrointestinal common infectious diseases (CIDs) and on immune functions in healthy shift workers.Methods: The study was single-center, randomized, double-blind, and controlled. Volunteers received 200 g/day of verum (n = 500) or control Product (n = 500) for 3 months; 1-month follow-up was carried out.Results: The cumulated number of CIDs (primary outcome) was not significantly different between groups. Because the Poisson distribution of the primary parameter did not fully fit the observed data, a post hoc categorical analysis was applied and showed a significantly lower cumulated number of CIDs in the verum group during the Product consumption phase (odds ratio [OR] = 0.75, 95% confidence interval [CI] 0.59–0.95, p = 0.017). Verum also reduc...
-
consumption of a Fermented Dairy Product containing the probiotic lactobacillus casei dn 114 001 reduces the duration of respiratory infections in the elderly in a randomised controlled trial
British Journal of Nutrition, 2010Co-Authors: E Guillemard, F Tondu, F Lacoin, Jurgen SchrezenmeirAbstract:Abstract Common infectious diseases (CID) of the airways and the gastrointestinal tract are still a considerable cause of morbidity and mortality in elderly. The present study examined the beneficial effect of a Dairy Product containing the probiotic strain Lactobacillus casei DN-114 001 (Fermented Product) on the resistance of free-living elderly to CID. The study was multicentric, double blind and controlled, involving 1072 volunteers (median age = 76.0 years) randomised for consumption of either 200 g/d of Fermented (n 537) or control (non-Fermented) Dairy Product (n 535) for 3 months, followed by an additional 1 month's follow-up. The results showed that, when considering all CID, the Fermented Product significantly reduced the average duration per episode of CID (6.5 v. 8 d in control group; P = 0.008) and the cumulative duration of CID (7 v. 8 d in control group; P = 0.009). Reduction in both episode and cumulative durations was also significant for all upper respiratory tract infections (URTI; P < 0.001) and for rhinopharyngitis (P < 0.001). This was accompanied with an increase of L. casei species in stools throughout the Fermented Product consumption (2-3.8 x 107 equivalents of colony-forming unit/g of stools, P < 0.001). The cumulative number of CID (primary outcome) was not different between groups nor was the CID severity, fever, pathogens' occurrence, medication, immune blood parameters and quality of life. The Fermented Product was safe and well tolerated. In conclusion, consumption of a Fermented Dairy Product containing the probiotic strain L. casei DN-114 001 in elderly was associated with a decreased duration of CID in comparison with the control group, especially for URTI such as rhinopharyngitis.
-
consumption of a Fermented Dairy Product containing the probiotic lactobacillus casei dn 114001 reduces the duration of respiratory infections in the elderly in a randomised controlled trial
British Journal of Nutrition, 2010Co-Authors: E Guillemard, F Tondu, F Lacoin, Jurgen SchrezenmeirAbstract:Abstract Common infectious diseases (CID) of the airways and the gastrointestinal tract are still a considerable cause of morbidity and mortality in elderly. The present study examined the beneficial effect of a Dairy Product containing the probiotic strain Lactobacillus casei DN-114 001 (Fermented Product) on the resistance of free-living elderly to CID. The study was multicentric, double blind and controlled, involving 1072 volunteers (median age = 76.0 years) randomised for consumption of either 200 g/d of Fermented (n 537) or control (non-Fermented) Dairy Product (n 535) for 3 months, followed by an additional 1 month's follow-up. The results showed that, when considering all CID, the Fermented Product significantly reduced the average duration per episode of CID (6.5 v. 8 d in control group; P = 0.008) and the cumulative duration of CID (7 v. 8 d in control group; P = 0.009). Reduction in both episode and cumulative durations was also significant for all upper respiratory tract infections (URTI; P < 0.001) and for rhinopharyngitis (P < 0.001). This was accompanied with an increase of L. casei species in stools throughout the Fermented Product consumption (2-3.8 x 107 equivalents of colony-forming unit/g of stools, P < 0.001). The cumulative number of CID (primary outcome) was not different between groups nor was the CID severity, fever, pathogens' occurrence, medication, immune blood parameters and quality of life. The Fermented Product was safe and well tolerated. In conclusion, consumption of a Fermented Dairy Product containing the probiotic strain L. casei DN-114 001 in elderly was associated with a decreased duration of CID in comparison with the control group, especially for URTI such as rhinopharyngitis.
Merit M Tabbers - One of the best experts on this subject based on the ideXlab platform.
-
Fermented milk containing bifidobacterium lactis dn 173 010 in childhood constipation a randomized double blind controlled trial
Pediatrics, 2011Co-Authors: Merit M Tabbers, Agata Chmielewska, Maaike G Roseboom, Catherine Perrin, Hania Szajewska, Nolwenn Crastes, Johannes B Reitsma, Obbe F Norbruis, Marc A. BenningaAbstract:BACKGROUND: Constipation is a frustrating symptom affecting 3% of children worldwide. A Fermented Dairy Product containing Bifidobacterium lactis strain DN-173 010 was effective in increasing stool frequency in constipated women. Our aim was to assess the effects of this Product in constipated children. METHODS: In this prospective randomized, double-blind, controlled trial, 159 constipated children (defecation frequency RESULTS: Eleven children did not return to any follow-up visit (5 in the probiotic group, 6 in the control group) and were therefore excluded from the final analysis. Thus, 74 children in each group were analyzed. The change in stool frequency from baseline to after 3 weeks of Product consumption increased in both groups, but the difference was not statistically significant (2.9 ± 3.2 in probiotic group versus 2.6 ± 2.6 in control group, P = .35). There were no serious adverse events. CONCLUSIONS: In constipated children, the Fermented Dairy Product containing B lactis strain DN-173 010 did increase stool frequency, but this increase was comparable in the control group. There is currently not sufficient evidence to recommend Fermented Dairy Products containing B lactis strain DN-173 010 in this category of patients. Future studies should focus on whether a longer period of probiotic Products is more effective in children who have a short history of constipation.
-
effect of the consumption of a Fermented Dairy Product containing bifidobacterium lactis dn 173 010 on constipation in childhood a multicentre randomised controlled trial ntrtc 1571
BMC Pediatrics, 2009Co-Authors: Merit M Tabbers, Agata Chmielewska, Maaike G Roseboom, Claire Boudet, Catherine Perrin, Hania Szajewska, Marc A. BenningaAbstract:Background Constipation is a frustrating symptom affecting 3% of children worldwide. Randomised controlled trials show that both polyethylene glycol and lactulose are effective in increasing defecation frequency in children with constipation. However, in 30–50%, these children reported abdominal pain, bloating, flatulence, diarrhoea, nausea and bad taste of the medication. Two recent studies have shown that the Fermented Dairy Product containing Bifidobacterium lactis strain DN-173 010 is effective in increasing stool frequency in constipation-predominant irritable bowel syndrome patients with a defecation frequency < 3/week and in constipated women with a defecation frequency < 3/week. Goal of this study is to determine whether this Fermented Dairy Product is effective in the treatment of constipated children with a defecation frequency < 3/week.
-
effect of the consumption of a Fermented Dairy Product containing bifidobacterium lactis dn 173 010 on constipation in childhood a multicentre randomised controlled trial ntrtc 1571
BMC Pediatrics, 2009Co-Authors: Merit M Tabbers, Agata Chmielewska, Maaike G Roseboom, Claire Boudet, Catherine Perrin, Hania Szajewska, Marc A. BenningaAbstract:Constipation is a frustrating symptom affecting 3% of children worldwide. Randomised controlled trials show that both polyethylene glycol and lactulose are effective in increasing defecation frequency in children with constipation. However, in 30–50%, these children reported abdominal pain, bloating, flatulence, diarrhoea, nausea and bad taste of the medication. Two recent studies have shown that the Fermented Dairy Product containing Bifidobacterium lactis strain DN-173 010 is effective in increasing stool frequency in constipation-predominant irritable bowel syndrome patients with a defecation frequency < 3/week and in constipated women with a defecation frequency < 3/week. Goal of this study is to determine whether this Fermented Dairy Product is effective in the treatment of constipated children with a defecation frequency < 3/week. It is a two nation (The Netherlands and Poland) double-blind, placebo-controlled randomised multicentre trial in which 160 constipated children (age 3–16 years) with a defecation frequency <3/week will be randomly allocated to consume a Fermented Dairy Product containing Bifidobacterium lactis DN-173 010 or a control Product, twice a day, for 3 weeks. During the study all children are instructed to try to defecate on the toilet for 5–10 minutes after each meal (3 times a day) and daily complete a standardized bowel diary. Primary endpoint is stool frequency. Secondary endpoints are stool consistency, faecal incontinence frequency, pain during defecation, digestive symptoms (abdominal pain, flatulence), adverse effects (nausea, diarrhoea, bad taste) and intake of rescue medication (Bisacodyl). Rate of success and rate of responders are also evaluated, with success defined as ≥ 3 bowel movements per week and ≤1 faecal incontinence episode over the last 2 weeks of Product consumption and responder defined as a subject reporting a stool frequency ≥ 3 on the last week of Product consumption. To demonstrate that the success percentage in the intervention group will be 35% and the success percentage in the control group (acidified milk without ferments, toilet training, bowel diary) will be 15%, with alpha 0.05 and power 80%, a total sample size of 160 patients was calculated. This study is aimed to show that the Fermented Dairy Product containing Bifidobacterium lactis strain DN-173 010 is effective in increasing stool frequency after 3 weeks of Product consumption in children with functional constipation and a defecation frequency < 3/week.
E Guillemard - One of the best experts on this subject based on the ideXlab platform.
-
effects of consumption of a Fermented Dairy Product containing the probiotic lactobacillus casei dn 114 001 on common respiratory and gastrointestinal infections in shift workers in a randomized controlled trial
Journal of The American College of Nutrition, 2010Co-Authors: E Guillemard, Tanguy Jerome, Annlaure Flavigny, Stephan De La Motte, Jurgen SchrezenmeirAbstract:Objective: The risk of infection may be increased in people under stress such as shift workers. This study examined the effect of a Fermented Dairy Product containing the probiotic Lactobacillus casei DN-114 001 (verum) on the incidence of respiratory and gastrointestinal common infectious diseases (CIDs) and on immune functions in healthy shift workers.Methods: The study was single-center, randomized, double-blind, and controlled. Volunteers received 200 g/day of verum (n = 500) or control Product (n = 500) for 3 months; 1-month follow-up was carried out.Results: The cumulated number of CIDs (primary outcome) was not significantly different between groups. Because the Poisson distribution of the primary parameter did not fully fit the observed data, a post hoc categorical analysis was applied and showed a significantly lower cumulated number of CIDs in the verum group during the Product consumption phase (odds ratio [OR] = 0.75, 95% confidence interval [CI] 0.59–0.95, p = 0.017). Verum also reduc...
-
consumption of a Fermented Dairy Product containing the probiotic lactobacillus casei dn 114 001 reduces the duration of respiratory infections in the elderly in a randomised controlled trial
British Journal of Nutrition, 2010Co-Authors: E Guillemard, F Tondu, F Lacoin, Jurgen SchrezenmeirAbstract:Abstract Common infectious diseases (CID) of the airways and the gastrointestinal tract are still a considerable cause of morbidity and mortality in elderly. The present study examined the beneficial effect of a Dairy Product containing the probiotic strain Lactobacillus casei DN-114 001 (Fermented Product) on the resistance of free-living elderly to CID. The study was multicentric, double blind and controlled, involving 1072 volunteers (median age = 76.0 years) randomised for consumption of either 200 g/d of Fermented (n 537) or control (non-Fermented) Dairy Product (n 535) for 3 months, followed by an additional 1 month's follow-up. The results showed that, when considering all CID, the Fermented Product significantly reduced the average duration per episode of CID (6.5 v. 8 d in control group; P = 0.008) and the cumulative duration of CID (7 v. 8 d in control group; P = 0.009). Reduction in both episode and cumulative durations was also significant for all upper respiratory tract infections (URTI; P < 0.001) and for rhinopharyngitis (P < 0.001). This was accompanied with an increase of L. casei species in stools throughout the Fermented Product consumption (2-3.8 x 107 equivalents of colony-forming unit/g of stools, P < 0.001). The cumulative number of CID (primary outcome) was not different between groups nor was the CID severity, fever, pathogens' occurrence, medication, immune blood parameters and quality of life. The Fermented Product was safe and well tolerated. In conclusion, consumption of a Fermented Dairy Product containing the probiotic strain L. casei DN-114 001 in elderly was associated with a decreased duration of CID in comparison with the control group, especially for URTI such as rhinopharyngitis.
-
consumption of a Fermented Dairy Product containing the probiotic lactobacillus casei dn 114001 reduces the duration of respiratory infections in the elderly in a randomised controlled trial
British Journal of Nutrition, 2010Co-Authors: E Guillemard, F Tondu, F Lacoin, Jurgen SchrezenmeirAbstract:Abstract Common infectious diseases (CID) of the airways and the gastrointestinal tract are still a considerable cause of morbidity and mortality in elderly. The present study examined the beneficial effect of a Dairy Product containing the probiotic strain Lactobacillus casei DN-114 001 (Fermented Product) on the resistance of free-living elderly to CID. The study was multicentric, double blind and controlled, involving 1072 volunteers (median age = 76.0 years) randomised for consumption of either 200 g/d of Fermented (n 537) or control (non-Fermented) Dairy Product (n 535) for 3 months, followed by an additional 1 month's follow-up. The results showed that, when considering all CID, the Fermented Product significantly reduced the average duration per episode of CID (6.5 v. 8 d in control group; P = 0.008) and the cumulative duration of CID (7 v. 8 d in control group; P = 0.009). Reduction in both episode and cumulative durations was also significant for all upper respiratory tract infections (URTI; P < 0.001) and for rhinopharyngitis (P < 0.001). This was accompanied with an increase of L. casei species in stools throughout the Fermented Product consumption (2-3.8 x 107 equivalents of colony-forming unit/g of stools, P < 0.001). The cumulative number of CID (primary outcome) was not different between groups nor was the CID severity, fever, pathogens' occurrence, medication, immune blood parameters and quality of life. The Fermented Product was safe and well tolerated. In conclusion, consumption of a Fermented Dairy Product containing the probiotic strain L. casei DN-114 001 in elderly was associated with a decreased duration of CID in comparison with the control group, especially for URTI such as rhinopharyngitis.
Maaike G Roseboom - One of the best experts on this subject based on the ideXlab platform.
-
Fermented milk containing bifidobacterium lactis dn 173 010 in childhood constipation a randomized double blind controlled trial
Pediatrics, 2011Co-Authors: Merit M Tabbers, Agata Chmielewska, Maaike G Roseboom, Catherine Perrin, Hania Szajewska, Nolwenn Crastes, Johannes B Reitsma, Obbe F Norbruis, Marc A. BenningaAbstract:BACKGROUND: Constipation is a frustrating symptom affecting 3% of children worldwide. A Fermented Dairy Product containing Bifidobacterium lactis strain DN-173 010 was effective in increasing stool frequency in constipated women. Our aim was to assess the effects of this Product in constipated children. METHODS: In this prospective randomized, double-blind, controlled trial, 159 constipated children (defecation frequency RESULTS: Eleven children did not return to any follow-up visit (5 in the probiotic group, 6 in the control group) and were therefore excluded from the final analysis. Thus, 74 children in each group were analyzed. The change in stool frequency from baseline to after 3 weeks of Product consumption increased in both groups, but the difference was not statistically significant (2.9 ± 3.2 in probiotic group versus 2.6 ± 2.6 in control group, P = .35). There were no serious adverse events. CONCLUSIONS: In constipated children, the Fermented Dairy Product containing B lactis strain DN-173 010 did increase stool frequency, but this increase was comparable in the control group. There is currently not sufficient evidence to recommend Fermented Dairy Products containing B lactis strain DN-173 010 in this category of patients. Future studies should focus on whether a longer period of probiotic Products is more effective in children who have a short history of constipation.
-
effect of the consumption of a Fermented Dairy Product containing bifidobacterium lactis dn 173 010 on constipation in childhood a multicentre randomised controlled trial ntrtc 1571
BMC Pediatrics, 2009Co-Authors: Merit M Tabbers, Agata Chmielewska, Maaike G Roseboom, Claire Boudet, Catherine Perrin, Hania Szajewska, Marc A. BenningaAbstract:Background Constipation is a frustrating symptom affecting 3% of children worldwide. Randomised controlled trials show that both polyethylene glycol and lactulose are effective in increasing defecation frequency in children with constipation. However, in 30–50%, these children reported abdominal pain, bloating, flatulence, diarrhoea, nausea and bad taste of the medication. Two recent studies have shown that the Fermented Dairy Product containing Bifidobacterium lactis strain DN-173 010 is effective in increasing stool frequency in constipation-predominant irritable bowel syndrome patients with a defecation frequency < 3/week and in constipated women with a defecation frequency < 3/week. Goal of this study is to determine whether this Fermented Dairy Product is effective in the treatment of constipated children with a defecation frequency < 3/week.
-
effect of the consumption of a Fermented Dairy Product containing bifidobacterium lactis dn 173 010 on constipation in childhood a multicentre randomised controlled trial ntrtc 1571
BMC Pediatrics, 2009Co-Authors: Merit M Tabbers, Agata Chmielewska, Maaike G Roseboom, Claire Boudet, Catherine Perrin, Hania Szajewska, Marc A. BenningaAbstract:Constipation is a frustrating symptom affecting 3% of children worldwide. Randomised controlled trials show that both polyethylene glycol and lactulose are effective in increasing defecation frequency in children with constipation. However, in 30–50%, these children reported abdominal pain, bloating, flatulence, diarrhoea, nausea and bad taste of the medication. Two recent studies have shown that the Fermented Dairy Product containing Bifidobacterium lactis strain DN-173 010 is effective in increasing stool frequency in constipation-predominant irritable bowel syndrome patients with a defecation frequency < 3/week and in constipated women with a defecation frequency < 3/week. Goal of this study is to determine whether this Fermented Dairy Product is effective in the treatment of constipated children with a defecation frequency < 3/week. It is a two nation (The Netherlands and Poland) double-blind, placebo-controlled randomised multicentre trial in which 160 constipated children (age 3–16 years) with a defecation frequency <3/week will be randomly allocated to consume a Fermented Dairy Product containing Bifidobacterium lactis DN-173 010 or a control Product, twice a day, for 3 weeks. During the study all children are instructed to try to defecate on the toilet for 5–10 minutes after each meal (3 times a day) and daily complete a standardized bowel diary. Primary endpoint is stool frequency. Secondary endpoints are stool consistency, faecal incontinence frequency, pain during defecation, digestive symptoms (abdominal pain, flatulence), adverse effects (nausea, diarrhoea, bad taste) and intake of rescue medication (Bisacodyl). Rate of success and rate of responders are also evaluated, with success defined as ≥ 3 bowel movements per week and ≤1 faecal incontinence episode over the last 2 weeks of Product consumption and responder defined as a subject reporting a stool frequency ≥ 3 on the last week of Product consumption. To demonstrate that the success percentage in the intervention group will be 35% and the success percentage in the control group (acidified milk without ferments, toilet training, bowel diary) will be 15%, with alpha 0.05 and power 80%, a total sample size of 160 patients was calculated. This study is aimed to show that the Fermented Dairy Product containing Bifidobacterium lactis strain DN-173 010 is effective in increasing stool frequency after 3 weeks of Product consumption in children with functional constipation and a defecation frequency < 3/week.